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Background: Whole-parasite immunization remains the benchmark in malaria vaccine development. A major
bottleneck in the translation of whole-parasite immunization towards routine vaccination is the mode of administration,
since high degrees of protection are currently only achieved by intravenous, and not by intradermal or subcutaneous
injection of viable parasites. It is known that only a small proportion of subcutaneously administered parasites reach the
subsequent liver stage and low parasite liver load was shown to be associated with low protective efficacy. The
objective of this analysis was to evaluate whether the liver load following subcutaneous parasite injection could be
augmented by co-administration of pro-inflammatory or anti-coagulatory drugs.
Methods: In the C57BL/6 Plasmodium berghei ANKA model, the clinical outcome (time to patent blood stage infection
and survival) and relative parasite liver load was assessed in mice infected by subcutaneous or intramuscular sporozoite
(SPZ) administration in the presence or absence of histamine and heparin supplementation in comparison to
intravenously administered SPZ. In addition, a vaccination experiment was carried out to assess the protective efficacy
of an improved, histamine-supplemented subcutaneous immunization regimen.
Results: The parasite liver load following subcutaneous SPZ administration can be significantly increased by
co-administration of histamine and heparin. A dose-dependent relation between parasite liver load and histamine
dosage was observed. However, despite a relatively high parasite liver load, the protective efficacy of
histamine-supplemented subcutaneous immunization remains inferior as compared to intravenous SPZ
administration.
Conclusions: Histamine supplementation might facilitate the future development of a non-intravenous
whole-parasite vaccine. Further investigations are needed to reveal the effect of histamine supplementation and
subcutaneous SPZ administration on the acquisition of protective immunity.
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For six decades, vaccination with whole attenuated para-
sites has remained the gold standard in malaria vaccine
development and is the only way to ensure complete
protection in vaccinated individuals. Following the first
report of protective immunity in mice receiving irradi-
ated sporozoites (SPZ) [1], the approach was transferred
to human trials and initially SPZ were delivered by the
bites of more than 1,000 irradiated infectious mosqui-
toes [2,3]. Since then, it has been shown that not only ir-
radiation, but also other modes of attenuation, such as
administration of protective drugs [4,5] and genetic
modification [6] can be used. Whole-parasite malaria
vaccination had been considered unfeasible for routine
vaccination until recently when it returned to the focus
of anti-malarial vaccine development following the de-
velopment of aseptic, purified, vialed, and cryopreserved
NF54 Plasmodium falciparum SPZ (PfSPZ vaccine) [7].
The initial clinical assessment of the irradiated PfSPZ vac-
cine reported limited immunogenicity and protection when
administered intradermally (id) [8]. However, intravenous
(iv) administration resulted in higher immunogenicity and
improved protective efficacy in a subsequent study [9].
Complementary studies in the rodent model demonstrated
that only a small number of id or subcutaneously (sc)
injected parasites reach the intrahepatic stage. Moreover re-
duced parasitic liver load was associated with low protective
efficacy following id SPZ administration [8,10].
Concerning the translation of whole-parasite im-
munization towards a routine malaria vaccine, highly
protective non-iv immunization regimens would be pre-
ferred especially when the vaccine is intended for the use in
paediatric populations. Thus, improving the infectivity of
non-iv SPZ administration routes is an important objective
for further development of whole-parasite vaccination.
In natural malaria infections, SPZ are transmitted to
humans by the bite of infective female Anopheles mos-
quitoes. The bite elicits an acute inflammatory reaction
at the feeding site, resulting from the saliva of mosqui-
toes that contains pro-inflammatory [11] as well as anti-
hemostatic [12] agents that facilitate the blood feeding
process. The hypothesis of this analysis is that the local
inflammatory reaction may not only benefit the feeding
mosquito but also improve the chances of parasites suc-
cessfully entering the blood stream and in turn, estab-
lishing a malaria infection in the mammalian host.
The objective of this study was to investigate the
infectivity of sc and intramuscular (im) SPZ administra-
tion in the presence or absence of both pro-inflammatory
(histamine) and anti-haemostatic (heparin) drugs in the
rodent C57BL/6 Plasmodium berghei (ANKA strain)
model. In addition, the protective efficacy of histamine-
supplemented sc whole-parasite immunization was
evaluated.Methods
Ethics statement
All animal experiments were performed according to
FELASA category B and GV-SOLAS standard guidelines.
Animal experiments were approved by German author-
ities (Regierungspräsidium Karlsruhe, Germany), § 8
Abs. 1 Tierschutzgesetz (TierSchG).Data assessment and statistical analysis
Data assessment and statistical analysis were performed
using Stata IC/13.0 (StataCorp LP, College Station, TX,
USA) and Prism Version 5.0b (GraphPad Software, San
Diego California, USA). Log rank-test was used to com-
pare survival distributions. Within groups of infected
animals, Student’s t-test or Mann–Whitney-U-test were
applied to compare parasite liver load detected by qRT-PCR
or in vivo bioluminescence measurement, as appropriate.
The clinical outcome of the final immunization experiment
was assessed using Fisher’s exact test.
Infection, immunization and challenge procedure
Freshly dissected P. berghei (ANKA strain) salivary gland
SPZ were injected into C57BL/6 mice either sc in the
neck skin fold, im in the thigh muscle or iv into the tail
vein. SPZ were administered in PBS in a total volume of
100 μl, supplemented with 5 IU of heparin (Heparin
5000 IU/ml, Ratiopharm GmbH, 89079 Ulm, Germany)
and varying amounts (1, 3 or 100 μg) of histamine
(10 mg/ml histamine-dihydrochlorid, ALK-prick, ALK-
Abell Arzneimittel GmbH, 22876 Wedel, Germany). For
im administration, the volume was reduced to 50 μl.
For immunization under chloroquine (CQ) chemo-
prophylaxis (chloroquine chemoprophylaxis with sporozo-
ites; CQ-CPS), mice were immunized by a prime-two boost
regimen administered iv or sc at weekly intervals. CQ
chemoprophylaxis was continuously supplied in the drink-
ing water (CQ-DW) as previously described [13] with an el-
evated CQ concentration (300 mg/l instead of 288 mg/l).
CQ-DW was introduced concomitant with the first (prime)
SPZ administration and maintained until 14 days after the
final (boost 2) immunization. Mice were challenged four
weeks after withdrawal of CQ-DW by iv injection of 104
freshly dissected P. berghei salivary gland SPZ.Parasitaemia read-out
Thin blood smears were obtained at days 4, 5, 7, 10, and
14 post-infection. Blood smears were Giemsa-stained
and 25 light fields, each representing approximately 400
single-layer erythrocytes, were assessed by light micros-
copy. Malaria infection was reported if at least two in-
fected red blood cells were detected within the same
slide on at least one occasion.
Figure 1 Survival time of malaria-infected animals. Animals were
infected by a single injection of 104 SPZ, administered either in PBS
(n = 10), or in PBS supplemented with 5 IU of heparin and 1 μg
(1 μg sc, n = 10) or 3 μg (3 μg sc, n = 10) of histamine.
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For quantification of the parasite load in the liver by
real-time qRT-PCR, C57BL/6 mice were infected with
104 SPZ iv or sc, with or without supplementation of
5 IU heparin and 3 μg or 100 μg of histamine.
Mice were sacrificed at 42 or 48 hours post-infection,
and livers were removed and homogenized. Total RNA
was isolated with the RNeasy kit (Qiagen), and comple-
mentary DNA (cDNA) was synthesized with the RET-
ROScript kit (Ambion), according to the manufacturer’s
instructions. Real-time PCR was performed with the ABI
7500 sequence detection system and Power SYBR Green
PCRMasterMix (Applied Biosystems), according to the
manufacturer’s instructions, using gene-specific primers
for the P. berghei 18SrRNA [GenInfo Identifier (GI),
160641] (forward: 5′-AAGCATTAAATAAAGCGAATAC
ATCCTTAC-3′; reverse: 5′-GGAGATTGGTTTTGACG
TTTATGTG-3′) and the mouse GAPDH gene (GI,
281199965) (forward: 5′-CGTCCCGTAGACAAAA
TGGT-3′; reverse:5′-TTGATGGCAACAATCTCCAC-3′).
Temperature profile was as follows: 95°C for 10 min,
followed by 40 cycles of 95°C for 15 sec, 55°C for 45 sec
and 60°C for 1 min.
In vivo quantification of parasite load
The transgenic P. berghei line 676m1cl1 (Pb GFP-
Luccon) [14] was used for in vivo imaging. Luciferase ac-
tivity was visualized using an in vivo imaging System
(IVIS 100; Caliper Life Sciences, USA) as previously de-
scribed [15]. In brief, animals were anesthetized using
isofluorane, their belly was shaved and de-haired. D-
luciferin (Synchem Laborgemeinschaft OHG, Germany)
was dissolved in PBS and a total of 2.5 mg/mouse were
injected intraperitoneally. Bioluminescence imaging was
acquired with an exposure time of 180 sec directly follow-
ing administration of D-luciferin and analysed using Liv-
ing Image 2.50.1 (Xenogen Corp., Hopkinton, MA, USA).
Results
Infection by subcutaneous SPZ with histamine and
heparin results in reduced prepatency and survival time
An initial experiment was conducted to assess the clin-
ical outcome of mice infected by sc injection of 104 SPZ,
administered either in PBS (n = 10), or in PBS supple-
mented with 5 IU of heparin and 1 μg (1 μg sc, n = 10)
or 3 μg (3 μg sc, n = 10) of histamine.
The addition of histamine and heparin decreased the
time period to first microscopic detection of parasites in
the blood smear (prepatency), and this effect seemed to be
dependent on the total dosage of histamine supplementa-
tion. Mean prepatency was 6.9 (95% CI 5.1-8.7), 6.5 (4.6-
8.4) and 5.5 (4.9-6.1) days in the sc, 1 μg sc and 3 μg sc
groups, respectively. In comparison to the sc group, prepa-
tency was significantly shortened in mice that receivedSPZ together with 3 μg histamine (P <0.05), but not in
those that received 1 μg histamine (P = 0.25). In all groups,
the mean prepatency was longer than expected after iv in-
fection (usually three to four days), which was confirmed
by a small group of four control animals infected with 104
SPZ iv (Figure 1). In addition, the survival time within
these groups of SPZ-infected animals was observed. The
mean survival time post-infection decreased from 10.8
(95% CI 9.9-11.7) to 10 (8.5-11.5) and 8.8 (8.3-9.3) days in
the sc, 1 μg sc and 3 μg sc groups, respectively. The sur-
vival time was significantly shortened in animals receiving
SPZ supplemented with 3 μg histamine versus sc controls
(P <0.001), but not in the 1 μg sc versus sc group (P = 0.22,
Figure 2).
Histamine supplementation of subcutaneously injected
SPZ increases the parasite liver burden
Following this clinical observation, further experiments
were conducted to evaluate whether parasitic liver bur-
den as determined by both qRT-PCR and in vivo im-
aging were increased in animals infected with SPZ plus
histamine compared to animals infected with SPZ in
PBS only. In animals infected sc by 104 SPZ in PBS sup-
plemented with 3 μg histamine and 5 IU of heparin
(3 μg sc; n = 9), the mean parasitic liver load was in-
creased by approximately 2.5-fold (P <0.05) as compared
to animals infected with 104 SPZ sc in PBS (sc; n = 11).
A wide inter-individual variance in parasite liver burden
was noted (Figure 3). Based on the clinical outcome de-
scribed above, a dose-dependent effect of histamine sup-
plementation on the resulting parasite liver load was
assumed. According to this hypothesis, further experi-
ments compared the parasite liver load of mice infected
subcutaneous with 104 SPZ in PBS (sc, n = 7), or in PBS
supplemented with 5 IU of heparin and either 3 μg (3 μg sc;
n = 7) or an increased dosage of 100 μg (100 μg sc; n = 5)
of histamine. The parasite liver load was calculated by the
Figure 2 Survival time of malaria-infected animals. Animals were
infected by a single injection of 104 SPZ, administered either in PBS
(n = 10), or in PBS supplemented with 5 IU of heparin and 1 μg
(1 μg sc, n = 10) or 3 μg (3 μg sc, n = 10) of histamine.
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reference. Four control mice were infected at the same
time point with equivalent doses of SPZ iv, and the liver
load of sc infected mice was expressed in relation to
the median liver load of these iv-infected control ani-
mals. The median relative liver burden detected was 2,
3 and 10% in the sc, 3 μg sc and 100 μg sc groups, re-
spectively, and subject to wide inter-individual variance
(Figure 4).
To validate the results obtained from qRT-PCR ana-
lysis, in vivo imaging was applied as a second read-out
for parasite liver development. Intrahepatic flux was
measured in mice infected sc with 104 luciferase-
expressing SPZ plus 5 IU of heparin and either 3 μg
(3 μg sc; n = 8) or 100 μg (100 μg sc; n = 8) histamine. InFigure 3 Relative 18S rRNA liver load following a single injection of 1
histamine and 5 IU heparin (3 μg his; n = 10) or in PBS only (sc; n = 9). Liveaddition, a group of mice receiving intramuscular injec-
tions of 104 luciferase-expressing SPZ and 100 μg hista-
mine with (n = 4) or without (n = 4) 5 IU of heparin was
included in the in vivo experiments. In this small ex-
periment, the addition or absence of heparin did not in-
fluence the parasite liver load of im infected mice
(Figure 5), and all animals were thus summarized in a
single group (100 μg im). As before, the intrahepatic
flux was expressed in relation to the median of four
simultaneously iv-infected control animals. The median
relative parasite liver load was 2, 9 and 7% for the sc
3 μg, sc 100 μg and im 100 μg group, respectively
(Figure 6).The parasite liver load following sc injection is scalable by
injection of increasing SPZ numbers
In preparation of subsequent immunization experiments,
it was assessed if a parasite liver load comparable to iv
SPZ administration could be achieved by combining his-
tamine supplementation with increasing numbers of sc-
injected SPZ.
Based on the previously determined relative parasite
liver load achieved by sc versus iv infection, two inde-
pendent experiments were designed to compare: A) the
parasite liver load in mice infected sc with 2*105 SPZ
plus 3 μg of histamine and 5 IU of heparin versus mice
infected with 104 SPZ iv; and B) the parasite liver load in
mice infected sc with 3*104 SPZ plus 100 μg of hista-
mine and 5 IU of heparin versus mice infected with 103
SPZ iv. In vivo measurement at 48 hrs post-infection
demonstrated that the mean parasite liver burden in sc-04 sporozoites. Animals were infected with SPZ sc in PBS plus 3 μg
r load was obtained at 42 hrs after infection.
Figure 4 Relative 18S rRNA liver load following subcutaneous infection in relation to intravenously infected control animals. Animals
were infected sc by a single injection of 104 SPZ. SPZ were administered either without supplementation (sc, n = 7) or supplemented with 3 μg
histamine and 5 IU heparin (3 μg sc; n = 7) or 100 μg histamine and 5 IU heparin (100 μg sc, n = 5). The liver load was obtained at 48 hrs after
infection and is expressed in relation to the median 18S rRNA liver load of four iv-infected control mice.
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animals (Additional file 1 Figures S1a and S1b).
Despite high parasite liver load, the protective capacity of
histamine-supplemented sc CQ-CPS remains inferior to
iv CQ-CPS
An immunization experiment was conducted to assess
the protective efficacy of whole parasite immunizationFigure 5 In vivo liver load following intramuscular in the presence or
single injection of 104 luciferase-expressing SPZ im supplemented with 100 μ
difference between heparin supplemented and non-supplemented mice wasdelivered by improved sc SPZ administration versus con-
ventional iv immunization. Groups of animals were in-
fected with a prime-two boost regimen of 3*104 SPZ
under CQ chemoprophylaxis either sc in PBS (CQ-CPS
sc; n = 6), with 3*104 SPZ sc in PBS supplemented with
5 IU heparin and 100 μg histamine (CQ-CPS 100 μg sc;
n = 8) or by 3*103 SPZ in PBS iv (CQ-CPS iv; n = 8). Fol-
lowing a challenge with 104 SPZ iv, it was observed thatabsence of heparin supplementation. Animals were infected by a
g histamine with (n = 4) or without (n = 4) 5 IU heparin. No significant
detected.
Figure 6 In vivo liver load in relation to intravenously infected control animals. Mice were infected with 104 SPZ supplemented with either
3 μg histamine and 5 IU heparin sc (3 μg s.; n = 8) or 100 μg histamine and 5 IU heparin sc (100 μg sc; n = 8) or 100 μg histamine with (n = 4) or
without (n = 4) 5 IU heparin im (mice are displayed combined in group 100 μg im; total n = 8). The intrahepatic flux was obtained at 48 hrs
post-infection and is expressed in relation to the median flux measurement of four iv-infected control mice.
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pletely protected from blood-stage infection, while six
out of eight animals in the CQ-CPS 100 μg sc group and
all animals in the CQ-CPS sc group developed blood-
stage infection. Thus, the rate of protected animals in
the CQ-CPS 100 μg sc and the CQ-CPS sc groups
remained significantly lower compared to the iv control
group (both P <0.01), while the difference between both
sc immunized groups was non-significant (P = 0.47;
Table 1). Despite the low protective capacity of sc
immunization against blood-stage infection, immunized
animals were still protected from severe malaria disease
as none of the immunized animals succumbed or devel-
oped signs of severe neurological disease (defined by a
rapid murine coma and behaviour scale <5) [16] until
day 14 post-challenge (Table 1).Table 1 Protection after chloroquine chemoprophylaxis with
Week CQ control CQ-CPS iv
n = 4 n = 8
Immunization/
drug treatment
(prime; boost 1; boost 2) 0; 1; 2
- /
CQ-DW
3 × 103 SPZ iv
CQ-DW
Challenge 8 104 SPZ iv 104 SPZ iv
Animals protected 0/4 8/8
Animals surviving by
day 14 post-challenge 1/4 8/8
CQ-DW: chloroquine supplemented drinking water; his: histamine; hep: heparin.
CQ-DW was maintained in all animals from prime immunization until 2 weeks after
*two animals died during the immunization process for unknown reasons.Discussion
This study in the rodent malarial model demonstrates
that the parasite liver load following sc or im SPZ injec-
tion can be increased by co-administration of heparin
and histamine. The increase in parasite liver burden
correlates with histamine supplementation in a dose-
dependent manner, while heparin supplementation
might be dispensable. Parasite liver load is thought to
be associated with protective efficacy achieved by whole-
parasite immunization [8,10]. Therefore, the concept of
histamine supplementation might represent an important
contribution to the ongoing efforts in the development of
an efficacious non-iv whole-parasite vaccine.
Within the analyses, it was found that supplementation
with 100 μg histamine and 5 IE heparin increases the
parasite liver burden by approximately five-fold assporozoites immunization
CQ-CPS 100 μg sc CQ-CPS sc
n = 8 n = 8
/ 3 × 104 SPZ + 100 μg his and 5IU hep sc /
CQ-DW
3 × 104 SPZ sc /
CQ-DW
104 SPZ iv 104 SPZ iv
2/8 0/6*
8/8 6/6
the final boost immunization.
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parasite liver load thereby reaches approximately 10% of
the level achieved by iv infection, which is superior to any
previous report on im, sc or id SPZ administration [17].
Importantly, sc histamine administration is not re-
stricted to the rodent model but has previously been
applied as an adjuvant to immunotherapy in oncologic
phase II and III clinical trials. Subcutaneous adminis-
tration of 1 mg histamine-dihydrochloride was found
to be safe [18], even when applied in an outpatient set-
ting [19]. A safety assessment in rats demonstrated
that repeated doses of 500 mg/kg or higher elicited
acute tissue damage, while the repeated injection of up
to 100 mg/kg did not result in relevant side effects be-
sides a local inflammatory reaction [20]. Thus, the con-
cept of histamine co-administration is likely to be safe
and feasible not only in the rodent model but also in
human whole-parasite vaccination.
The increase in parasitic liver obtained through histamine
co-administration has to be interpreted with caution as it
might be explained by two different mechanisms. Firstly,
the local inflammation and vasodilation induced by hista-
mine injection may increase the number of SPZ entering a
capillary and thus increase the total number of parasites
reaching the liver stage. It is known that the majority of id
administered SPZ remain in the skin for hours before
entering the bloodstream and invading a hepatocyte,
whereas iv-injected SPZ reach the liver within minutes
[21]. Thus, it cannot be excluded that co-administration
of histamine enables SPZ to enter the blood stream at
an earlier time point rather than in greater number. In
this case, the increasing parasite liver load detected at a
single time point post-infection might not, or only in
parts, represent an increase in total liver load over time
but rather a shift of the maximum liver burden to earl-
ier time points post-infection. For the same reason, de-
termination of the parasite liver load obtained by sc
versus iv administration at a single time point post-
infection represents a minimal and thus conservative
estimate of the real total liver load obtained by sc injec-
tion. While it would be desirable to determine parasite
liver burden over time, such measurements remains
technically challenging as in vivo detection of intrahepa-
tic liver development at later time points is masked by
increasing blood-stage infection.
A previous study attempted to enhance the protective im-
munogenicity of injections either by topical application of
imiquimod or by local ‘tape-stripping’ of the skin at the in-
fection site. Interestingly, mice immunized by SPZ injected
at a tape-stripped skin site demonstrated superior protection
against a subsequent "by bite" SPZ challenge [22]. Tape-
stripping of the injection is likely to induce local inflamma-
tion, and the superior protection reported might indicate
that local inflammation increases the number of SPZreaching the liver and thereby augments the total parasite
liver load.
In a CPS vaccination experiment, the protective efficacy
of a prime-two boost sc immunization regimen supple-
mented with 100 μg histamine and 5 IU heparin was com-
pared versus a non-supplemented sc control group and an
iv control group immunized by a ten-fold lower SPZ dos-
age. Despite the earlier observation of at least 50% parasite
liver burden in histamine-supplemented sc versus iv
immunized animals, the protection achieved by histamine-
supplemented sc immunization remained inferior in com-
parison to the iv control group and was at best slightly
higher than in the non-supplemented sc immunized con-
trols. While it cannot completely be excluded that a slightly
lower parasite liver load might sufficiently explain this in-
ferior protection, additional factors might contribute to the
decreased efficacy of sc CQ-CPS immunization. It is pos-
sible that a high number of SPZ remaining in the animals’
tissue enables the development of invasion-blocking anti-
bodies during the prime immunization, thus leading to a
decreased parasite liver load in subsequent immunizations
[10]. Alternatively, immune responses induced by SPZ
remaining in the skin or draining lymph nodes [23] or a
histamine-triggered increasing activity of myeloid suppressor
cells [24] might impede the development of protective cellu-
lar intrahepatic immune responses. The specific reasons for
the low protection induced by repeated sc immunization are
an important question for future investigations. Additional
approaches and measures like e.g. intradermal SPZ adminis-
tration [22], SPZ administration at lower volumes [21] or by
microneedle patches [25], or the use of radiation attenuated
SPZ rather than CPS might be combined with the concept
of histamine supplementation to develop a highly protective
non-iv SPZ immunization regimen.
In the meantime, the current data suggests that even
though sc immunization was insufficient to protect
against blood-stage infection, it still seems to prevent
the onset of experimental cerebral malaria. This observa-
tion could be explained by blood-stage directed immune
responses induced by CPS [26] and might represent an
additional benefit obtained by CPS immunization. In
summary, histamine supplementation represents a novel
and conceptually innovative approach that could con-
tribute to the future development of a non-iv whole-
parasite malaria vaccines.
Conclusions
Histamine supplementation of sc-injected SPZ increases
the parasite liver load in a dose-dependent manner. This
novel concept might contribute to the future development
of an efficacious non-iv whole-parasite vaccine. Further
investigation is required to reveal the underlying causes of
inferior protective efficacy obtained by sc immunization in
comparison to the iv gold standard.
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Additional file 1: Enhancement of parasitic liver load by increased
numbers of injected sporozoites. In two independent experiments, the
in vivo parasitic liver load at 48 hrs after infection was assessed in A) mice
infected sc with 2*105 SPZ supplemented with 3 μg histamine and 5 IU of
heparin (2*105 + 3 μg sc; n = 4) versus control mice infected iv with 104 SPZ
(104 iv; n = 4) and B) in mice infected with 3*104 SPZ supplemented with
3 μg histamine and 5 IU of heparin sc (3*104 + 100 μg sc; n = 3) versus
control mice infected iv with 3*103 SPZ iv (3*103 iv; n = 3). Large intra-
individual differences in the intrahepatic parasite burden were observed, with-
out significant differences between sc and iv-infected animals in experiment A)
while the liver load of sc-infected animals remained approximately half of the iv
control group in experiment B).
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